PCJ Stock Chart & Stats
€5.47
€0.00(0.00%)
At close: 4:00 PM EDT
€5.47
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.56 - €6.28
Previous CloseN/A
Volume0.00
Average Volume (3M)76.00
Market Cap
€303.18M
Enterprise Value€108.56
Total Cash (Recent Filing)€168.27M
Total Debt (Recent Filing)€23.17M
Price to Earnings (P/E)4.7
Beta1.08
Next Earnings
Aug 12, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.28
Shares Outstanding56,995,144
10 Day Avg. Volume30
30 Day Avg. Volume76
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.30Price Target Upside216.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.66
Revenue Forecast (FY)€58.09M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue TractionAbeona’s early commercial launch produced meaningful revenue ($8.7M Q1 2026), demonstrating initial product-market fit and billing capability. Durable commercialization traction supports scaling revenue, validates manufacturing/clinical processes, and underpins a path to recurring cash generation as volumes increase.
Payer CoveragePublished coverage for 95% of commercially insured lives materially reduces reimbursement risk for a high-cost gene therapy. Durable payer acceptance improves revenue predictability, eases patient access barriers, and supports sustainable utilization as the QTC network and physician referrals expand over months.
Manageable LeverageLow debt relative to equity provides financial flexibility to fund commercialization and planned development without immediate refinancing pressure. A stronger balance sheet than prior years reduces solvency risk and supports capital deployment for QTC expansion and IND-enabling work.
Bears Say
Negative Operating Cash FlowSustained, large negative operating and free cash flow (~-$78M and -$85M TTM) signals heavy cash burn from commercialization and R&D. This creates reliance on external financing, which can dilute shareholders or constrain investment timing if revenue ramps slower than forecast, threatening runway.
Earnings Quality DisconnectReported positive net income despite deeply negative EBIT/EBITDA indicates earnings are influenced by non-operating or one-time items. This disconnect undermines confidence in sustainable profitability and complicates forecasting cash conversion and true operating performance over coming quarters.
Elevated Operating ExpensesMaterial SG&A increases and commercialization costs raise the fixed cost base while revenue is still nascent. With variable onboarding times and multi-month activation delays per QTC, expense growth may outpace revenue scale, extending the timeline to operating breakeven and pressuring margins.
Abeona Therapeutics News
PCJ FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was €3.56 and its highest was €6.28 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is €303.18M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 15 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on May 13, 2026. The company reported -€0.264 earnings per share for the quarter, beating the consensus estimate of -€0.295 by €0.031.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.2.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 56,995,144 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -€0.264 in its last earnings report, beating expectations of -€0.295. Following the earnings report the stock price went down -2.861%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in DE:PCJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.30 (216.36% Upside)
€17.30 (216.36% Upside)
Blogger Sentiment
Bullish
DE:PCJ Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
99.76%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
PCJ Company Deck
PCJ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear early commercial momentum for ZEVASKYN (notable revenue acceleration, 95% published commercial coverage, growing QTC network and manufacturing success with no harvest failures) and meaningful pipeline advancement with the in-licensed PSMA SIR-T program. Offsetting these positives are elevated operating expenses (notably SG&A), a larger reported net loss driven partly by a $7M upfront license payment, a declining cash balance, and operational / payer timing risks (variable biopsy lead times and lengthy insurance approvals for out-of-state Medicaid). On balance, the positives — strong initial revenue growth, payer coverage, successful manufacturing outcomes and a targeted oncology asset with limited near-term spend — outweigh the near-term financial and operational challenges.View all DE:PCJ earnings summariesPCJ Stock 12 Month Forecast
Average Price Target
€17.30
▲(216.36% Upside)